Reported Earnings • May 17
Full year 2026 earnings released: EPS: ₹0.84 (vs ₹0.99 in FY 2025) Full year 2026 results: EPS: ₹0.84 (down from ₹0.99 in FY 2025). Revenue: ₹672.6m (up 19% from FY 2025). Net income: ₹32.3m (down 15% from FY 2025). Profit margin: 4.8% (down from 6.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • May 08
Hindcon Chemicals Limited to Report Q4, 2026 Results on May 14, 2026 Hindcon Chemicals Limited announced that they will report Q4, 2026 results on May 14, 2026 New Risk • Apr 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.9% net profit margin). Market cap is less than US$100m (₹1.19b market cap, or US$12.8m). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹19.31, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years. New Risk • Mar 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹936.3m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.7% per year over the past 5 years. Market cap is less than US$10m (₹936.3m market cap, or US$9.99m). Minor Risk Profit margins are more than 30% lower than last year (4.9% net profit margin). New Risk • Feb 04
New major risk - Revenue and earnings growth Earnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.7% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.9% net profit margin). Market cap is less than US$100m (₹1.17b market cap, or US$12.9m). Reported Earnings • Feb 04
Third quarter 2026 earnings released: EPS: ₹0.08 (vs ₹0.35 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.08 (down from ₹0.35 in 3Q 2025). Revenue: ₹142.3m (down 6.8% from 3Q 2025). Net income: ₹3.23m (down 76% from 3Q 2025). Profit margin: 2.3% (down from 8.9% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹20.21, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 12% over the past three years. New Risk • Aug 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹1.72b market cap, or US$19.6m). Announcement • Aug 11
Hindcon Chemicals Limited, Annual General Meeting, Sep 23, 2025 Hindcon Chemicals Limited, Annual General Meeting, Sep 23, 2025. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹37.73, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 173% over the past three years. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹30.79, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 121% over the past three years. Reported Earnings • Jan 30
Third quarter 2025 earnings released: EPS: ₹0.35 (vs ₹0.26 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.35 (up from ₹0.26 in 3Q 2024). Revenue: ₹161.3m (up 20% from 3Q 2024). Net income: ₹13.6m (up 37% from 3Q 2024). Profit margin: 8.5% (up from 7.4% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹2.14b market cap, or US$24.7m). New Risk • Nov 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₹2.47b market cap, or US$29.2m). Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹48.20, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 328% over the past three years. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹56.46, the stock trades at a trailing P/E ratio of 58.3x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 348% over the past three years. Reported Earnings • Aug 10
First quarter 2025 earnings released: EPS: ₹0.34 (vs ₹0.66 in 1Q 2024) First quarter 2025 results: EPS: ₹0.34 (down from ₹0.66 in 1Q 2024). Revenue: ₹132.7m (down 23% from 1Q 2024). Net income: ₹13.0m (down 48% from 1Q 2024). Profit margin: 9.8% (down from 15% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Aug 06
Upcoming dividend of ₹0.10 per share Eligible shareholders must have bought the stock before 13 August 2024. Payment date: 19 September 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%). New Risk • Aug 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₹2.86b market cap, or US$34.1m). Announcement • Jul 16
Hindcon Chemicals Limited, Annual General Meeting, Aug 20, 2024 Hindcon Chemicals Limited, Annual General Meeting, Aug 20, 2024. Recent Insider Transactions • Jun 22
Chairman & MD recently bought ₹2.0m worth of stock On the 19th of June, Sanjay Goenka bought around 40k shares on-market at roughly ₹49.42 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Sanjay has been a buyer over the last 12 months, purchasing a net total of ₹5.2m worth in shares. Buy Or Sell Opportunity • May 19
Now 21% overvalued Over the last 90 days, the stock has fallen 15% to ₹53.25. The fair value is estimated to be ₹43.96, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 9.4%. Board Change • May 07
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Divyaa Newatia was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹59.10, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 1,043% over the past three years. Buy Or Sell Opportunity • Apr 03
Now 20% overvalued Over the last 90 days, the stock has fallen 4.4% to ₹53.25. The fair value is estimated to be ₹44.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 9.4%. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹52.05, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 1,020% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹59.70, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1,211% over the past three years. Buy Or Sell Opportunity • Feb 01
Now 19% overvalued after recent price rise Over the last 90 days, the stock has risen 85% to ₹49.65. The fair value is estimated to be ₹41.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 9.4%. Reported Earnings • Feb 01
Third quarter 2024 earnings released: EPS: ₹0.26 (vs ₹0.37 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.26 (down from ₹0.37 in 3Q 2023). Revenue: ₹134.4m (down 50% from 3Q 2023). Net income: ₹9.99m (down 29% from 3Q 2023). Profit margin: 7.4% (up from 5.3% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 112% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₹49.05, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 932% over the past three years. Recent Insider Transactions • Sep 03
Whole Time Director recently bought ₹2.0m worth of stock On the 29th of August, Nilima Goenka bought around 14k shares on-market at roughly ₹144 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹3.4m more in shares than they have sold in the last 12 months. Reported Earnings • Aug 14
First quarter 2024 earnings released: EPS: ₹3.32 (vs ₹1.35 in 1Q 2023) First quarter 2024 results: EPS: ₹3.32 (up from ₹1.35 in 1Q 2023). Revenue: ₹176.9m (down 16% from 1Q 2023). Net income: ₹25.3m (up 147% from 1Q 2023). Profit margin: 14% (up from 4.9% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 95% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 13
Hindcon Chemicals Limited to Report Q1, 2024 Results on Aug 12, 2023 Hindcon Chemicals Limited announced that they will report Q1, 2024 results on Aug 12, 2023 New Risk • Aug 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (₹1.03b market cap, or US$12.4m). Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹112, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 633% over the past three years. Announcement • Aug 03
Hindcon Chemicals Limited, Annual General Meeting, Aug 26, 2023 Hindcon Chemicals Limited, Annual General Meeting, Aug 26, 2023, at 14:00 Indian Standard Time. Location: Hindusthan Club Limited, 4/1, Sarat Bose Road, 2nd Floor Kolkata-700 020 Kolkata India Agenda: To receive, consider and adopt the Standalone and Consolidated Financial Statement of the Company including Audited Balance Sheet as at 31 March, 2023, Audited Statement of Profit and Loss and the Cash Flow Statement for the year ended as on that date together with Report of Directors' and Auditors' thereon; to appoint a Director in place of Mr. Ramsanatan Banerjee, retiring by rotation and being eligible, offered himself for re-appointment; and to consider other business matters. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹94.55, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 939% over the past three years. Recent Insider Transactions • Mar 27
Whole Time Director recently bought ₹63k worth of stock On the 24th of March, Nilima Goenka bought around 786 shares on-market at roughly ₹79.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹450k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹1.84 (vs ₹1.39 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.84 (up from ₹1.39 in 3Q 2022). Revenue: ₹266.4m (up 60% from 3Q 2022). Net income: ₹14.0m (up 32% from 3Q 2022). Profit margin: 5.3% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Dec 27
Chairman & MD recently bought ₹263k worth of stock On the 22nd of December, Sanjay Goenka bought around 3k shares on-market at roughly ₹87.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sanjay's only on-market trade for the last 12 months. Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹0.71 (vs ₹0.97 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.71 (down from ₹0.97 in 2Q 2022). Revenue: ₹190.5m (up 25% from 2Q 2022). Net income: ₹5.41m (down 27% from 2Q 2022). Profit margin: 2.8% (down from 4.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment improved over the past week After last week's 46% share price gain to ₹126, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 703% over the past three years. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹76.80, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 391% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 20% share price gain to ₹87.40, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 462% over the past three years. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 15% share price gain to ₹73.45, the stock trades at a trailing P/E ratio of 18.7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 372% over the past three years. Upcoming Dividend • Aug 11
Upcoming dividend of ₹0.70 per share Eligible shareholders must have bought the stock before 18 August 2022. Payment date: 25 September 2022. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (0.7%). Announcement • Aug 06
Hindcon Chemicals Limited, Annual General Meeting, Aug 26, 2022 Hindcon Chemicals Limited, Annual General Meeting, Aug 26, 2022, at 13:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹49.65, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 180% over the past three years. Reported Earnings • May 31
Full year 2022 earnings released Full year 2022 results: Revenue: ₹679.9m (up 53% from FY 2021). Net income: ₹42.3m (down 6.4% from FY 2021). Profit margin: 6.2% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Girdhari Goenka was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improved over the past week After last week's 21% share price gain to ₹75.50, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 354% over the past three years. Reported Earnings • Feb 15
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹1.39 (down from ₹1.61 in 3Q 2021). Revenue: ₹169.9m (up 31% from 3Q 2021). Net income: ₹10.6m (down 14% from 3Q 2021). Profit margin: 6.3% (down from 9.5% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 24% share price gain to ₹70.20, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 305% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 24% share price gain to ₹70.20, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 305% over the past three years. Reported Earnings • Nov 10
Second quarter 2022 earnings released: EPS ₹0.97 (vs ₹1.48 in 2Q 2021) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹155.8m (up 48% from 2Q 2021). Net income: ₹7.41m (down 34% from 2Q 2021). Profit margin: 4.8% (down from 11% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 20
First quarter 2021 earnings released: EPS ₹1.47 (vs ₹0.72 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: ₹77.0m (down 25% from 1Q 2020). Net income: ₹11.3m (up 104% from 1Q 2020). Profit margin: 15% (up from 5.4% in 1Q 2020). The increase in margin was driven by lower expenses. Upcoming Dividend • Aug 19
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 26 August 2021. Payment date: 13 September 2021. Trailing yield: 2.3%. Within top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹41.75, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 105% over the past three years. Recent Insider Transactions • Jul 02
Whole Time Director recently bought ₹743k worth of stock On the 29th of June, Nilima Goenka bought around 20k shares on-market at roughly ₹37.17 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹2.6m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • May 21
Investor sentiment improved over the past week After last week's 20% share price gain to ₹32.55, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improved over the past week After last week's 17% share price gain to ₹25.80, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹20.25, the stock is trading at a trailing P/E ratio of 5.5x, down from the previous P/E ratio of 6.5x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past year are 76%. Is New 90 Day High Low • Feb 18
New 90-day low: ₹24.00 The company is down 4.0% from its price of ₹25.00 on 20 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period. Recent Insider Transactions • Jan 30
MD & Director recently bought ₹100k worth of stock On the 27th of January, Sanjay Goenka bought around 4k shares on-market at roughly ₹25.08 per share. In the last 3 months, they made an even bigger purchase worth ₹209k. Sanjay has been a buyer over the last 12 months, purchasing a net total of ₹2.6m worth in shares. Recent Insider Transactions • Jan 16
MD & Director recently bought ₹201k worth of stock On the 13th of January, Sanjay Goenka bought around 8k shares on-market at roughly ₹25.18 per share. In the last 3 months, they made an even bigger purchase worth ₹209k. Sanjay has been a buyer over the last 12 months, purchasing a net total of ₹2.5m worth in shares. Recent Insider Transactions • Jan 06
MD & Director recently bought ₹305k worth of stock On the 29th of December, Sanjay Goenka bought around 12k shares on-market at roughly ₹25.41 per share. This was the largest purchase by an insider in the last 3 months. Sanjay has been a buyer over the last 12 months, purchasing a net total of ₹2.6m worth in shares. Recent Insider Transactions • Dec 07
MD & Director recently bought ₹209k worth of stock On the 4th of December, Sanjay Goenka bought around 8k shares on-market at roughly ₹26.18 per share. This was the largest purchase by an insider in the last 3 months. Sanjay has been a buyer over the last 12 months, purchasing a net total of ₹2.1m worth in shares. Valuation Update With 7 Day Price Move • Nov 18
Market bids up stock over the past week After last week's 15% share price gain to ₹22.45, the stock is trading at a trailing P/E ratio of 6.1x, up from the previous P/E ratio of 5.3x. This compares to an average P/E of 16x in the Chemicals industry in India. Is New 90 Day High Low • Nov 15
New 90-day high: ₹19.70 The company is up 11% from its price of ₹17.80 on 17 August 2020. The Indian market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period. Recent Insider Transactions • Oct 03
Whole Time Director recently bought ₹660k worth of stock On the 30th of September, Nilima Goenka bought around 36k shares on-market at roughly ₹18.34 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.4m. Insiders have collectively bought ₹2.5m more in shares than they have sold in the last 12 months. 
